Pulmonary Arterial Hypertension in Connective Tissue Diseases

Heart Failure Clinics

Volumn 8, Issue 3, 2012, Pages 413-425

  Mathai, Stephen C ^a   Hassoun, Paul M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Connective tissue disease; Mixed connective tissue disease; Pulmonary hypertension; Scleroderma; Systemic lupus erythematosus; Therapy

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; AMBRISENTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AUTOANTIBODY; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; CD31 ANTIGEN; CELL ADHESION MOLECULE; CORTICOSTEROID; ENDOGLIN; HLA B35 ANTIGEN; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNIPROST; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANGIOGENESIS; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG SAFETY; DRUG TOLERABILITY; EARLY DIAGNOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY CELL; LIVER TOXICITY; LUNG EDEMA; LUNG TRANSPLANTATION; MIXED CONNECTIVE TISSUE DISEASE; MORTALITY; PATHOGENESIS; PERIPHERAL EDEMA; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; RAYNAUD PHENOMENON; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN SYNDROME; SURVIVAL; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS; TELANGIECTASIA; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; VASODILATATION;

AUTOANTIBODIES; GENETIC PREDISPOSITION TO DISEASE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; POLYMORPHISM, GENETIC; PROGNOSIS; PROTEIN-TYROSINE KINASES; RISK FACTORS; SCLERODERMA, SYSTEMIC; TIME FACTORS;

EID: 84863084082     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.04.001     Document Type: Review

References (126)

1. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
2. Gaine S.P., Rubin L.J. Primary pulmonary hypertension. Lancet 1998, 352:719-725.
3. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987, 107:216-223.
4. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54:S43-S54.
5. Budhiraja R., Tuder R.M., Hassoun P.M. Endothelial dysfunction in pulmonary hypertension. Circulation 2004, 109:159-165.
6. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351:1425-1436.
7. Isern R.A., Yaneva M., Weiner E., et al. Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku. Am J Med 1992, 93:307-312.
8. Humbert M., Monti G., Brenot F., et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995, 151:1628-1631.
9. Kawut S.M., Taichman D.B., Archer-Chicko C.L., et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003, 123:344-350.
10. Fisher M.R., Mathai S.C., Champion H.C., et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006, 54:3043-3050.
11. Condliffe R., Kiely D.G., Peacock A.J., et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009, 179:151-157.
12. Jimenez S.A., Derk C.T. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004, 140:37-50.
13. Tan F.K. Systemic sclerosis: the susceptible host (genetics and environment). Rheum Dis Clin North Am 2003, 29:211-237.
14. LeRoy E.C., Black C., Fleischmajer R., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
15. Mayes M.D. Scleroderma epidemiology. Rheum Dis Clin North Am 2003, 29:239-254.
16. Silman A., Jannini S., Symmons D., et al. An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol 1988, 27:286-290.
17. Tamaki T., Mori S., Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 1991, 283:366-371.
18. Allcock R.J., Forrest I., Corris P.A., et al. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) 2004, 43:596-602.
19. Mayes M.D., Lacey J.V., Beebe-Dimmer J., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003, 48:2246-2255.
20. Hachulla E., Gressin V., Guillevin L., et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005, 52:3792-3800.
21. Mukerjee D., St George D., Coleiro B., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003, 62:1088-1093.
22. Battle R.W., Davitt M.A., Cooper S.M., et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996, 110:1515-1519.
23. Stupi A.M., Steen V.D., Owens G.R., et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986, 29:515-524.
24. Sacks D.G., Okano Y., Steen V.D., et al. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol 1996, 23:639-642.
25. MacGregor A.J., Canavan R., Knight C., et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001, 40:453-459.
26. Fisher M.R., Forfia P.R., Chamera E., et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009, 179:615-621.
27. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006, 173:1023-1030.
28. Peacock A.J., Murphy N.F., McMurray J.J., et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007, 30:104-109.
29. Badesch D.B., Raskob G.E., Elliott C.G., et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010, 137:376-387.
30. LeRoy E.C. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996, 22:675-694.
31. Fleischmajer R., Perlish J.S. Capillary alterations in scleroderma. J Am Acad Dermatol 1980, 2:161-170.
32. Sgonc R., Gruschwitz M.S., Boeck G., et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000, 43:2550-2562.
33. Cerinic M.M., Valentini G., Sorano G.G., et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 2003, 32:285-295.
34. Altman R.D., Medsger T.A., Bloch D.A., et al. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991, 34:403-413.
35. Denton C.P., Bickerstaff M.C., Shiwen X., et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995, 34:1048-1054.
36. Distler O., Del Rosso A., Giacomelli R., et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002, 4:R11.
37. Choi J.J., Min D.J., Cho M.L., et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003, 30:1529-1533.
38. Hebbar M., Peyrat J.P., Hornez L., et al. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 2000, 43:889-893.
39. Okano Y., Steen V.D., Medsger T.A. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992, 35:95-100.
40. Negi V.S., Tripathy N.K., Misra R., et al. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998, 25:462-466.
41. Fritzler M.J., Hart D.A., Wilson D., et al. Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis. J Rheumatol 1995, 22:1688-1693.
42. Morse J.H., Barst R.J., Fotino M., et al. Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7. Am J Respir Crit Care Med 1997, 155:274-278.
43. Grigolo B., Mazzetti I., Meliconi R., et al. Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35. Clin Exp Immunol 2000, 121:539-543.
44. Nicolls M.R., Taraseviciene-Stewart L., Rai P.R., et al. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005, 26:1110-1118.
45. Tamby M.C., Chanseaud Y., Humbert M., et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005, 60:765-772.
46. Chizzolini C., Raschi E., Rezzonico R., et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002, 46:1602-1613.
47. Tamby M.C., Humbert M., Guilpain P., et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J 2006, 28:799-807.
48. Terrier B., Tamby M.C., Camoin L., et al. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008, 177:1128-1134.
49. Sanchez O., Sitbon O., Jais X., et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006, 130:182-189.
50. Deng Z., Morse J.H., Slager S.L., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000, 67:737-744.
51. Lane K.B., Machado R.D., Pauciulo M.W., et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000, 26:81-84.
52. Newman J.H., Trembath R.C., Morse J.A., et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 2004, 43:33S-39S.
53. Koehler R., Grunig E., Pauciulo M.W., et al. Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension. J Med Genet 2004, 41:e127.
54. Morse J.H., Deng Z., Knowles J.A. Genetic aspects of pulmonary arterial hypertension. Ann Med 2001, 33:596-603.
55. Trembath R.C., Thomson J.R., Machado R.D., et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001, 345:325-334.
56. Morse J., Barst R., Horn E., et al. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol 2002, 29:2379-2381.
57. Tew M.B., Arnett F.C., Reveille J.D., et al. Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases. Arthritis Rheum 2002, 46:2829-2830.
58. Karrer S., Bosserhoff A.K., Weiderer P., et al. The -2518 promoter polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 2005, 124(1):92-98.
59. Tsuchiya N., Kuroki K., Fujimoto M., et al. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 2004, 50:4002-4007.
60. Tolusso B., Fabris M., Caporali R., et al. -238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with systemic sclerosis. Immunol Lett 2005, 96:103-108.
61. Kawaguchi Y., Tochimoto A., Ichikawa N., et al. Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population. Arthritis Rheum 2003, 48:186-192.
62. Hutyrova B., Lukac J., Bosak V., et al. Interleukin 1alpha single-nucleotide polymorphism associated with systemic sclerosis. J Rheumatol 2004, 31:81-84.
63. Crilly A., Hamilton J., Clark C.J., et al. Analysis of the 5' flanking region of the interleukin 10 gene in patients with systemic sclerosis. Rheumatology (Oxford) 2003, 42:1295-1298.
64. Zhou X., Tan F.K., Wang N., et al. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 2003, 48:2585-2592.
65. Wipff J., Kahan A., Hachulla E., et al. Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 2007, 46:622-625.
66. Schachna L., Wigley F.M., Chang B., et al. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003, 124:2098-2104.
67. Chang B., Schachna L., White B., et al. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006, 33:269-274.
68. Steen V., Medsger T.A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003, 48:516-522.
69. Allanore Y., Borderie D., Avouac J., et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008, 58:284-291.
70. Shah A.A., Wigley F.M., Hummers L.K. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J Rheumatol 2010, 37(1):98-104.
71. Hsiao S.H., Lee C.Y., Chang S.M., et al. Right heart function in scleroderma: insights from myocardial Doppler tissue imaging. J Am Soc Echocardiogr 2006, 19:507-514.
72. Lee C.Y., Chang S.M., Hsiao S.H., et al. Right heart function and scleroderma: insights from tricuspid annular plane systolic excursion. Echocardiography 2007, 24:118-125.
73. Meune C., Avouac J., Wahbi K., et al. Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 2008, 58:1803-1809.
74. Overbeek M.J., Lankhaar J.W., Westerhof N., et al. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur Respir J 2008, 31:1160-1166.
75. Williams M.H., Handler C.E., Akram R., et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006, 27:1485-1494.
76. Forfia P.R., Mathai S.C., Fisher M.R., et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008, 177:1364-1369.
77. Williams M.H., Das C., Handler C.E., et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006, 92:926-932.
78. Koh E.T., Lee P., Gladman D.D., et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996, 35:989-993.
79. McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002, 106:1477-1482.
80. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944.
81. Pope J. An update in pulmonary hypertension in systemic lupus erythematosus-do we need to know about it?. Lupus 2008, 17:274-277.
82. Haas C. Bull Acad Natl Med 2004, 188:985-997. [discussion: 997], [in French].
83. Sullivan W.D., Hurst D.J., Harmon C.E., et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 1984, 63:92-107.
84. Launay D., Hachulla E., Hatron P.Y., et al. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 2007, 86:299-315.
85. Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995, 333:214-221.
86. Tuder R.M., Cool C.D., Geraci M.W., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999, 159:1925-1932.
87. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328:1732-1739.
88. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992, 327:76-81.
89. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005, 111:3105-3111.
90. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association. Circulation 2009, 119(16):2250-2294.
91. Vane J.R., Anggard E.E., Botting R.M. Regulatory functions of the vascular endothelium. N Engl J Med 1990, 323:27-36.
92. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296-302.
93. McLaughlin V.V., Genthner D.E., Panella M.M., et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998, 338:273-277.
94. Rubin L.J., Mendoza J., Hood M., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990, 112:485-491.
95. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132:425-434.
96. Badesch D.B., McGoon M.D., Barst R.J., et al. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol 2009, 36:2244-2249.
97. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800-804.
98. Tapson V.F., Gomberg-Maitland M., McLaughlin V.V., et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006, 129:683-688.
99. Farber H.W., Graven K.K., Kokolski G., et al. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J Rheumatol 1999, 26:1195-1196.
100. Palmer S.M., Robinson L.J., Wang A., et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998, 113:237-240.
101. Galie N., Manes A., Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis 2002, 45:213-224.
102. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001, 358:1119-1123.
103. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
104. Denton C.P., Humbert M., Rubin L., et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006, 65:1336-1340.
105. Girgis R.E., Mathai S.C., Krishnan J.A., et al. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 2005, 24:1626-1631.
106. Iannone F., Riccardi M.T., Guiducci S., et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2008, 67:1121-1126.
107. Jain M., Varga J. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers. Expert Opin Pharmacother 2006, 7:1487-1501.
108. Girgis R.E., Frost A.E., Hill N.S., et al. Selective endothelin a receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann. Rheum. Dis. 2007, 66(11):1467-1472.
109. Galie N., Olschewski H., Oudiz R.J., et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117:3010-3019.
110. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157.
111. Badesch D.B., Hill N.S., Burgess G., et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007, 34:2417-2422.
112. Galie N., Brundage B.H., Ghofrani H.A., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903.
113. McLaughlin V.V., Oudiz R.J., Frost A., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174:1257-1263.
114. Hoeper M.M., Faulenbach C., Golpon H., et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004, 24:1007-1010.
115. Simonneau G., Rubin L.J., Galie N., et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149:521-530.
116. Mathai S.C., Girgis R.E., Fisher M.R., et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007, 29:469-475.
117. Fuster V., Steele P.M., Edwards W.D., et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984, 70:580-587.
118. Adnot S. Lessons learned from cancer may help in the treatment of pulmonary hypertension. J Clin Invest 2005, 115:1461-1463.
119. Schermuly R.T., Dony E., Ghofrani H.A., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115:2811-2821.
120. Moreno-Vinasco L., Gomberg-Maitland M., Maitland M.L., et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 2008, 33:278-291.
121. Ghofrani H.A., Morrell N.W., Hoeper M.M., et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010, 182(9):1171-1177.
122. Grigoryev D.N., Mathai S.C., Fisher M.R., et al. Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res 2008, 151:197-207.
123. ten Freyhaus H., Dumitrescu D., Bovenschulte H., et al. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 2009, 98:265-267.
124. Schachna L., Medsger T.A., Dauber J.H., et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006, 54:3954-3961.
125. Saggar R., Khanna D., Furst D.E., et al. Systemic sclerosis and bilateral lung transplantation: a single center experience. Eur Respir J 2010, 36(4):893-900.
126. Dorfmuller P., Humbert M., Perros F., et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007, 38:893-902.